Oral Lisinopril Raises Tissue Levels of ACE2, the SARS-CoV-2 Receptor, in Healthy Male and Female Mice
Reads0
Chats0
TLDR
In this paper, the authors sought to determine whether lisinopril or losartan, as monotherapies or in combination, change tissue levels of ACE2 in healthy male and female mice.Abstract:
Angiotensin-converting enzyme 2 (ACE2) is the established cellular receptor for SARS-CoV-2. However, it is unclear whether ACE1 inhibitors (e.g., lisinopril) or angiotensin receptor blockers (e.g., losartan) alter tissue ACE2 expression. This study sought to determine whether lisinopril or losartan, as monotherapies or in combination, change tissue levels of ACE2 in healthy male and female mice. Mice were treated for 21 days with drinking water containing lisinopril (10 mg/kg/day), losartan (10 mg/kg/day), or both. A control group was given water without drug. ACE2 protein index, the ratio of ACE2 protein to total protein, was determined on tissues from the small intestine, lung, kidney, and brain. Oral lisinopril increased ACE2 protein index across all tissues (pread more
References
More filters
Journal ArticleDOI
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Keiji Kuba,Yumiko Imai,Shuan Rao,Hong Gao,Feng Guo,Bin Guan,Yi Huan,Peng Yang,Yanli Zhang,Wei Deng,Linlin Bao,Binlin Zhang,Guang Liu,Zhong Wang,Mark C. Chappell,Yanxin Liu,Dexian Zheng,Andreas Leibbrandt,Teiji Wada,Arthur S. Slutsky,Depei Liu,Chuan Qin,Chengyu Jiang,Josef M. Penninger +23 more
TL;DR: A molecular explanation why SARS-CoV infections cause severe and often lethal lung failure and suggest a rational therapy for SARS and possibly other respiratory disease viruses is provided.
A Systematic Review and Meta-analysis
TL;DR: A systematic review of studies published from January 1, 1950, through November 31, 2008 using PubMed, EMBASE, Web of Knowledge, CINAHL, and all Evidence-Based Medicine Reviews found that randomized clinical trials and prospective studies of RRTs that reported data on changes in the primary outcome of hospital mortality or the secondary outcome of cardiopulmonary arrest cases were included.
Journal ArticleDOI
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
Vanessa Monteil,Hyesoo Kwon,Patrícia Rezende do Prado,Astrid Hagelkruys,Reiner A. Wimmer,Martin Stahl,Alexandra Leopoldi,Elena Garreta,Carmen Hurtado del Pozo,Felipe Prosper,Juan P. Romero,Gerald Wirnsberger,Haibo Zhang,Arthur S. Slutsky,Ryan K. Conder,Nuria Montserrat,Ali Mirazimi,Ali Mirazimi,Josef M. Penninger,Josef M. Penninger +19 more
TL;DR: It is demonstrated that hrsACE2 can significantly block early stages of SARS-CoV-2 infections, and is proposed that inhibiting this interaction might be used in treating patients with COVID-19.
Journal ArticleDOI
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
Muthiah Vaduganathan,Orly Vardeny,Thomas Michel,John J.V. McMurray,Marc A. Pfeffer,Scott D. Solomon +5 more
TL;DR: RAAS Inhibitors in Patients with Covid-19 show low levels of renin–angiotensin-converting enzyme 2 levels and activity in humans, but the effects are still uncertain.
Journal ArticleDOI
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.
Carlos M. Ferrario,Jewell A. Jessup,Mark C. Chappell,David B. Averill,K. Bridget Brosnihan,E. Ann Tallant,Debra I. Diz,Patricia E. Gallagher +7 more
TL;DR: Although the predominant effect of ACE inhibition may result from the combined effect of reduced Ang II formation and Ang-(1–7) metabolism, the antihypertensive action of AT1 antagonists may in part be due to increased Ang II metabolism by ACE2.